Document is current
Any future updates will be listed below
-
Authors
Barnbrock, Anke
Berger, Annemarie
Lauten, Melchior
Demmert, Martin
Klusmann, Jan-Henning
Ciesek, Sandra
Bochennek, Konrad
Lehrnbecher, Thomas https://orcid.org/0000-0002-6022-3439
-
Funding
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 21 June 2024
First Online: 27 June 2024
Competing interests
: M.L<b>.</b> has served as consultant to EUSA Pharma and served at the speaker´s bureau of MSD. J.H.K has advisory roles for Bluebird Bio, Novartis, Roche and Jazz Pharmaceuticals. S.C. has received a grant from Roche Diagnostics, and served at the speaker´s bureau of Sanofi. K.B. served at the speaker´s bureau of MSD. T.L. has received a grant from Gilead Sciences, has served as consultant to Gilead Sciences, Merck/MSD, Pfizer, Astellas, AstraZeneca, EUSA Pharma and Roche, and served at the speaker´s bureau of Gilead Sciences, Merck/MSD, Astellas, Pfizer and GSK and EUSA Pharma. None of the other authors has to declare a conflict of interest regarding this work.
